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VENOUS COMPLIANCE 
 
MAJOR PROFESSOR:  Philip M. Anton 
 
There is evidence that arterial compliance can be lower in an individual who has 
undergone chemotherapy, but to date it has not been investigated as to whether the same 
is true for venous compliance. Investigate differences in the venous compliance in cancer 
survivors and healthy individuals. Twenty participants, 10 of whom were cancer 
survivors (CS=63.2 ± 6.7yrs), while the remaining 10 were healthy individuals (C=60.2 ± 
6.7yrs) underwent submaximal graded exercise tests and assessment of calf venous 
compliance.  Utilizing venous occlusion plethysmography, calf venous compliance was 
determined in both groups as the first derivative of the pressure-volume relation during 
cuff pressure reduction. Body mass (CS=73.5 ± 14.8 kg, C=82.3 ± 15.5 kg); height 
(CS=165.1 ± 7.9 cm, C=170.4 ± 14.8 cm); VO2 peak (CS=34.7 ± 9.6 𝑚𝑙 ∙ 𝑘𝑔−1 ∙
mi𝑛−1, C=40.9 ± 9.8 𝑚𝑙 ∙ 𝑘𝑔−1 ∙ mi𝑛−1 ); and resting blood pressures were not 
significantly different between the groups. Resting heart rate was (CS=76 ± 8.2 bpm, 
C=67.9 ± 8.9 bpm; 𝜌 < 0.05) was significantly greater in cancer survivors.  There were 
no differences in calf venous compliance, capacitance or capillary filtration volumes 
between the sexes. Results from this study indicate venous compliance is not different 
among cancer survivors who have received neuro-toxic or cardio-toxic 
chemotherapeutics and healthy individuals. 
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CHAPTER 1 
INTRODUCTION 
Vascular compliance is a term used to describe the ability of the blood vessel wall to 
expand and contract passively with changes in pressure. Seventy percent of total blood volume in 
humans can be located within the distensible veins upon standing (orthostatic pressure) or 
experiencing lower body negative pressure (LBNP) (Freeman, Wieling, Benditt, Axelrod, & 
Benarroch, 2011; Gelman, 2008. Skoog , Zachrisson , Lindenberger, Ekman, Ewerman, & 
Lanne, 2014; Lida, et al., 2011). The translocation of blood that occurs in the lower extremities 
in response to orthostatic changes elicits reflex responses (increase in heart rate and peripheral 
arterial resistance) that allow us to maintain venous return, blood pressure and cerebral perfusion 
(Freeman, Wieling, Benditt, Axelrod, & Benarroch, 2011; Hernandez, et al., 2004; Mosqueda-
Garcia, Furlan, Tank, & Fernandez-Violante, 2000).   
Many pathophysiological conditions have been associated with irregular arterial 
compliance, such as hypertension, diabetes and venous insufficiency (Delaney, Young, 
DiSabatino, Stillabower, & Farquhar, 2008; Goulopoulou, Deruisseau, Carhart Jr., & Kanaley, 
2012). One such morbidity, brought on by the sympathetic nervous systems’ improper control of 
arterial compliance, is known as diastolic heart failure. This condition is characterized by a stiff 
left ventricle with decreased compliance and impaired relaxation. Vasoconstriction, or increased 
resistance to blood flow, can be stimulated by the sympathetic nervous system (SNS) which 
produces a hormonal cascade resulting in the secretion of catecholamines (especially epinephrine 
and norepinephrine). Under ordinary circumstances, the autonomic nervous system keeps arterial 
vessel tone balanced. However, if the SNS is stimulating the smooth muscles of the arterial 
vessels for prolonged periods of time, complications can arise.  
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Autonomic nervous system impairment, or neuropathy, is a nervous system disorder 
affecting the control of involuntary functions, including digestion, heart rate, blood pressure, and 
perspiration. Neuropathy has already been shown to result from the treatment of various 
chemotherapeutics currently being used in oncologic medicine. The research team led by Adams 
was recently able to successfully link neuropathy found in cancer patients who had received four 
rounds of chemotherapy to aberrant blood pressure changes and maladaptive orthostatic 
responses (Adams, 2015). If patients are showing signs of poor orthostatic responses as a result 
of autonomic nervous system dysfunction, the veins of the lower body are likely being affected 
in some manner. That said, how the venous compliance of the lower limbs is being affected by 
this phenomenon is still unknown.  
Various cancer therapeutics, such as anthracyclines, are associated with increased risk for 
cardiovascular complications (Criscitiello, Metzger-Filho, & Saini, 2012; Chen, Xu, & Li, 2011; 
Hedhli , 2011; Volkova & Russell, 2011; ETH, 2009). Anthracyclines are dose-dependent in 
how they initiate cardio-toxicity (Cortes-Funtes & Coronado, 2007). This cardio-toxicity often 
contributes to cardiomyopathy and congestive heart failure, which is associated with the drugs’ 
interaction with iron, and production of potent reactive oxygen species (Jones , Stoner, Brown, 
Baldi, & McLaren, 2013). Furthermore, among women who have survived breast cancer, 
mortality due to cardiovascular disease is more common than cancer-related death, (Jones , 
Stoner, Brown, Baldi, & McLaren, 2013). Of these women, 45% of all cardiovascular-related 
deaths in individuals over the age of 55 years were attributed to coronary artery disease, which 
triggers a decline in arterial compliance resulting in higher peripheral blood pressure, among 
other effects (Jones , Stoner, Brown, Baldi, & McLaren, 2013). A peak in mortality due to 
circulatory system disorders appears at approximately 5 years’ post-diagnosis.  This may be 
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indicative of the fact that the impact of chemotherapeutics on the circulatory system may be 
chronic rather than acute (Jones , Stoner, Brown, Baldi, & McLaren, 2013). Doxorubicin, for 
example, is a cardio-toxic drug that can lower the hearts pumping capability, hindering the 
hearts’ total stroke volume. Such a result from taking chemotherapeutics could cause 
abnormalities in heart rate, which if left unsupervised, could lead to future cardiac events. This 
coupled with the possibility of having higher arterial stiffness could force heart rate to increase 
during exercise. 
 Other chemotherapeutics like paclitaxel can inhibit the growth of smooth muscle cells 
found in blood vessel walls (Axel, et al., 1997). Inhibiting the overall proliferation and migration 
of vascular smooth muscle cells could be a detriment to the healthy development and function of 
the vascular system, taking place over a period of time rather than an immediate change in 
vasculature health. Furthermore, disruption of endothelial cell health could further disrupt the 
processes carried out by the smooth muscle cells (Francois et al, 2006).  
With the vascular smooth muscle cells composing a portion of the extracellular matrix, 
this proliferation, inhibition, or exacerbation could upset the overall conformation of the matrix. 
With elastin being the structure that allows for the majority of venous passive elasticity, which 
also resides in the extracellular matrix, it is possible that changes to the vascular smooth muscle 
cells and disruption of the endothelial cells could impact the function of elastin (Francois et al, 
2006). With too little a ratio of smooth muscle to elastin, such a matrix composition could result 
in a vessel that is overly elastic and subject to greater expansion during pressure increases. The 
end result of this compositional change would most likely be blood pooling. Conversely, if a 
matrix has an excessive quantity of smooth muscle, the vessel may be overly resistant to 
expansion and contraction, increasing blood pressure. Both composition situations would prove 
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to be damaging to the overall status of the cancer survivors’ health. This warrants a greater 
understanding to what extent the compositional changes occur, which would allow for the 
necessary medical actions to take place to assure no further damage is done to the integrity of the 
vessel walls; thus, preventing further circulation stresses.  
If damage is done to the venous endothelial lining, the scarring and healing process 
produces tissue that is often limited in its compliance or elasticity (Huang et al, 2014). The 
pathophysiology of cancer survivors developing various cardiovascular conditions is still not a 
fully understood sequence of events. Specifically, the venous compliance changes associated 
with chemotherapeutic treatment require further study. Researchers have yet to examine whether 
any changes occur in venous compliance due to chemotherapeutics (Jones, Stoner, Brown, Baldi, 
& McLaren, 2013; Makari-Judson, Braun, Jerry, & Mertens, 2014). The exact chemotherapeutics 
being examined were determined by the impact the individual medications had on each 
participants’ body: anthracyclines such as Doxorubicin (Adriamycin), Epirubicin, Idarubicin, 
Daunorubicin, and medications that exhibit neurotoxic affects much like Paclitaxel, and 
Docetaxel (Taxotere). The study called for both men and women to account for the differences in 
circulatory characteristics, as women are more susceptible to orthostatic stress than men are 
(Lindenberger & Lanne, 2007; Lindenberger & Lanne, 2007).  
The purpose of this study was to use venous occlusive plethysmography (VOP) to 
measure the venous compliance within the calves of cancer survivors who had undergone 
specific chemotherapy and determine if the measures were markedly different than the 
compliance of apparently healthy individuals who are age and physical activity-matched.  
We hypothesize that venous compliance would be consistently lower in cancer survivors 
than the compliance of similar healthy individuals. The independent variables within the study 
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were the healthy participants and the treatments taken by the cancer survivors while the 
dependent variable were the resultant venous compliance of both groups. The results found 
within this study should be generalizable to cancer patients of varying physical activity levels 
who have taken similar chemotherapeutics to those received by the participants of the study. 
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CHAPTER 2 
METHODS 
Participants 
The sample size consisted of 20 participants, 10 (8 females, 2 males) of whom have gone 
through chemotherapy (Cancer Survivor=CS), and 10 ( 5 females, 5 males) healthy participants 
(Control=C) who were low risk asymptomatic men and women who have ≤1 CVD 
(Cardiovascular disease) risk factor and have not been diagnosed with cancer. The age of the 
cancer survivors (63.2 ± 6.7yrs) was similar to that of the age of the healthy participants (60.2 ± 
6.7yrs). Physical activity engagement for the CS group was also closely matched to the physical 
activity engagement of the C group. Exclusion criteria included patients who have received 
surgery rather than drug therapy and participants with a family history of heart and circulation 
events/disease.  
Screening 
 Participants were given a medical history and physical activity history form to complete. 
The participants’ blood pressure, heart rate, body composition, height, and weight were then 
measured. The participants were told to refrain from consuming any caffeine, alcohol, and/or 
dietary supplements 24 hours prior to testing.  
Venous Occlusion Plethysmography (VOP) 
 Changes in calf volume were evaluated with strain-gauge plethysmography. The 
instrument (Hokanson: EC5R-Plethysmograph) was used to measure volume changes (ml 100 
ml−1) of a limb by measuring the circumference. Data was recorded in a temperature-controlled 
room (24-26 ℃). Participants were placed in a supine position where they were put through an 
acclimation period of 15 minutes with their right leg or dominant leg slightly elevated with 
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support located at the ankle. Maximal calf size was measured, as the strain gauge was placed on 
this location. A 22-cm-wide thigh cuff was placed on the thigh proximal to the knee on the left 
leg. The cuff was then inflated to 60 mmHg using a cuff inflator (Hokanson: E20 Rapid Cuff 
Inflator, AG101 Cuff Inflator Air Source). After 8 minutes of venous stasis, cuff pressure was 
reduced by 1 mmHg per second in a linear fashion (Halliwill J. M., 1999). 
Calf Venous Compliance  
 Calf venous compliance (𝐶𝑐𝑎𝑙𝑓, ml 100 ml
−1 mmHg−1) was calculated from the 
pressure-volume relationship during the deflation phase. Data below 10 mmHg was excluded 
from analysis due to the potentially less reliable relation between cuff pressure and venous 
pressure at that level (Halliwill, Lawler , Eickhoff, Joyner, & Mulvagh, 1998; Halliwill, Minson, 
& Joyner, 1998; Skoog , Zachrisson , Lindenberger, Ekman, Ewerman, & Lanne, 2014). Venous 
pressure-volume curves were non-linear, with a steeper slope at greater compliance and a flatter 
slope at lower compliance. Characteristics of the pressure-volume curves from deflation readings 
were described as a quadratic regression equation (Halliwill, Lawler , Eickhoff, Joyner, & 
Mulvagh, 1998; Halliwill, Minson, & Joyner, 1998): 
∆Volume =   β0 + β1  ×  (cuff pressure +  β2  ×  (cuff Pressure)^2 
 β0 was the y-intercept and together β1 and β2 were characteristics of the slope generated 
by the pressure-volume curve. 𝐶𝑐𝑎𝑙𝑓 was defined as the first derivative of the pressure-volume 
curve, creating a linear pressure-compliance curve: 
𝐶𝑐𝑎𝑙𝑓 =    β1 + 2 × β2  ×  (cuff Pressure) 
 The slope of this curve equals the derivative of the pressure-compliance curve (slope = 2 
×  β2) and the regression parameters β1 and β2 was used as estimates for 𝐶𝑐𝑎𝑙𝑓 . Use of a t-test 
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between the cancer survivors and the general population regarding typical venous compliance 
measurements were necessary to view any differences in compliance between the two groups.  
Submaximal Fitness Assessment  
 Each participant completed his or her involvement with the study by performing a graded 
submaximal treadmill test to determine fitness level (Modified Bruce Protocol). Peak oxygen 
uptake (VO2) was estimated in all participants using time to termination of a modified Bruce 
treadmill protocol. The Modified Bruce Protocol has 2 warmup stages, each of which lasting 3 
minutes. The first was at a speed of 1.7 mph and a grade of 0%, while the second was at a speed 
of 1.7 mph and a grade of 5%. Each subsequent stage lasted 3 minutes and increased in grade 
and/or speed until the participant reached 65% of the difference between their age-predicted 
maximal heart rate and resting heart rate (Target heart rate). The test was terminated when the 
participant reached their THR or 12-13 on the RPE scale. The protocol is used most often in 
older individuals or those whose exercise capacity is limited by cardiac disease.  Pre-exercise 
resting heart rate and blood pressure measurements were taken. Heart rate was measured using a 
Polar Heart Rate MonitorTM. Blood pressure was measured manually using a pressure cuff on the 
upper arm. Heart rate and blood pressure was recorded during each stage. To minimize risks 
associated with a submaximal exercise test, the researcher (who was CPR certified) was 
constantly at the participants’ side to help reduce risk. The researcher kept close track of 
heartrate, blood pressure, and the exertion levels perceived by the participant. If the participant 
felt uncomfortable or did not wish to continue the test due to feeling unsafe, the researcher 
immediately terminated the exercise test. The participant was also able to stop the test whenever 
they wished. Each participant continued to walk on the treadmill at a very low intensity until 
their heart rate had returned to resting levels. Participants had their fitness testing results given to 
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them upon completion of the testing. They were explained the importance of the test results as 
well as given a handout showing their results.  
Analysis 
 The data gathered from the research was recorded on a Dell PC (Biopac Data Acquisition 
Software) which was then used for analysis. The resultant pressure-volume curves following the 
initial decrease in pressure were expressed by a quadratic regression 
equation[∆LV=β1+β2*(Cuff Pressure)+β2*(Cuff Pressure)2]. The group-average regression 
parameters 𝛽1 and 𝛽2 were applied together as an estimate of compliance 
[Compliance=β1+2*β2*(Cuff Pressure)]. The initial derivative yields a linear pressure-
compliance relationship and this slope was used to determine differences amongst participants 
who had gone through chemotherapy to those who had not.  
 The capacitance response was computed from the volume rise at the onset of cuff 
pressure to the line defined from the filtration slope between 3 and 8 minutes of cuff pressure 
application. Total capillary filtration during cuff pressure application was calculated from the 
rate of filtration (ml/min) times the time of the cuff pressure application (8 min). Total calf 
volume increase was the sum of the capacitance and net capillary filtration volumes.  
 Anthropometric and compliance (β’s) variables were compared between cancer 
participants and healthy participants using an independent t-test (PASW 18). Statistical 
significance was set at 𝜌<0.05. All data are presented as means ± SD (pg. 11-12). 
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CHAPTER 3 
RESULTS 
Participants Characteristics 
 Anthropometric characteristics and resting cardiovascular variables of all participants are 
displayed in Table 1. The cancer survivors (63.2 ± 6.7 yrs) and healthy individuals (60.2 ± 6.7 
yrs) did not vary significantly with respect to age. Body mass (CS=73.5 ± 14.8 kg, C=82.3 
± 15.5 kg); height (CS=165.1 ± 7.9 cm, C=170.4 ± 14.8 cm); VO2 peak (CS=34.7 ± 9.6 𝑚𝑙 ∙
𝑘𝑔−1 ∙ mi𝑛−1, C=40.9 ± 9.8 𝑚𝑙 ∙ 𝑘𝑔−1 ∙ mi𝑛−1 ); calf volume (CS=3710 ± 810 ml, C=4540 ± 
1510 ml); and resting blood pressures were not significantly different between the groups. 
Resting heart rate (CS=76 ± 8.2 bpm, C=67.9 ± 8.9 bpm; 𝜌 < 0.05) was significantly greater in 
cancer survivors. 
Table 1.  Anthropometric Data for all Participants 
Variable Cancer Healthy 
Age, yr 63.2 ± 6.7 60.2 ± 6.7 
Weight, kg 73.5 ± 14.8  82.3 ± 15.5  
Height, cm 165.1 ± 7.9 170.4 ± 14.8 
VO2peak, ml · kg -1 · 
min-1 34.7 ± 9.6  40.9 ± 9.8  
SBP, mmHg 119.3 ± 15.4 131.1 ± 15.3 
DBP, mmHg 75.5 ± 11.2  73.8 ± 8.9 
HR, beats/min 76 ± 8.2 67.9 ± 8.9*  
Calf Volume, ml 3710 ± 810  4540 ± 1510  
   
Values are mean and SD from 20 participants, 10 cancer survivors ad 10 healthy 
individuals; VO2peak, peak oxygen uptake; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; HR, heart rate; * p <0.05 vs. cancer survivor.  
 
Venous compliance 
 The regression parameters calculated for calf venous compliance β0, β1, β2 (mean ± SD) 
are presented in Table 2 (Below). There were no significant differences in calf pressure volume 
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curves (Figure 1, Table 2) or venous compliance slopes (Figure 2, Table 2). Capacitance and 
capillary filtration volumes (Figure 3) also did not differ between cancer survivors and healthy 
individuals.  
Table 2.  Calf Volume pressure volume regression equations 
Group Cancer 
  
  
Calf 
 
∆LV = 1.308  ±  1.097 + 0.083 ± 0.066 ∗ (𝐶𝑢𝑓𝑓) + −0.0006 ±
0.0013 ∗ (𝑐𝑢𝑓𝑓)2 
  
 Healthy 
  
Calf 
 
 
∆LV = 1.147 ± 0.843 + 0.07 ±  0.049 ∗  (𝐶𝑢𝑓𝑓) + −0.0005  ±
 0.001 ∗  (𝑐𝑢𝑓𝑓)2 
 
∆LV, change in limb volume; CP, cuff pressure 
[∆limb volume = βο + β1 * (cuff pressure) + β2 (cuff pressure)²] 
 
 
Figure 1.  Pressure-Volume relationship.  Data points are mean ± SEM 
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Figure 
2. 
 
 
 
 
Figure 3. Capacitance and Capillary Filtration. Data points are mean ± SEM 
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CHAPTER 4 
DISCUSSION 
  The purpose of this investigation was to determine if differences in venous compliance 
exist between cancer survivors who have received cardio-toxic or neuro-toxic chemotherapeutics 
and that of healthy age and physical activity-matched individuals. The primary finding of the 
current investigation revealed that our collected data indicated no differences in venous 
compliance between cancer survivors and healthy individuals.  Therefore, the data do not support 
our hypothesis that cancer survivors who have received cardio-toxic or neuro-toxic 
chemotherapeutics would have lower compliance compared to healthy individuals.  
Potential Mechanisms 
 Venous and arterial compliance is known to decline with age and improve with chronic 
exercise (Monahan K.D., 2001; Monahan, 2004; Hernandez, et al., 2004). The mechanisms 
eliciting such changes in compliance of vessels are potentially related to either structural changes 
in the ratio of elastin to collagen within the vessel wall, or to alterations in sympathetically 
mediated vascular tone. In relation to the venous wall, it is observed that aging decreases 
compliance through compositional changes to the elastin-to-collagen ratio (Bouissou, 1991), 
which makes it the most likely contributor to decreases in venous compliance. Noted arterial 
compliance changes in relation to the use neuro-toxic chemotherapeutics are more likely elicited 
by improper stimulation of sympathetic hormones inducing the smooth muscle of the vessel to 
constrict. The lack of smooth muscle found in the veins indicates that such sympathetic 
stimulation would not severly change venous compliance in an individual taking such 
chemotherapeutics. This further indicates that any potential changes in venous compliance are 
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related to compositional changes of the elastin-to-collagen ratio rather than sympathetic 
activation. 
While the present study did not show any differences between the two groups, it is 
possible that any potential decreases in venous compliance that may be caused by 
chemotherapeutics in the CS group would be negated by an active lifestyle. One study 
comparing individuals with less physically active peers revealed venous compliance was 50% 
greater in more fit young and older groups (Hernandez, et al., 2004). The participants used in the 
present study were part of an exercise program in which exercise takes place at least two days 
out of the week. Each participant has been apart of the program for greater than year. It has been 
observed that older individuals who participate in at least 6 months of exercise training generated 
enough stimulus to elicit significant improvements in calf venous compliance. Longer durations 
of training may elicit greater changes in calf venous compliance. One study observed the venous 
compliance of older individuals who had been running for at least 2 years and found their 
compliance to be 70-120% higher than their sedentary peers (Monahan K.D., 2001).  
 There are a number of limitations that require consideration when reviewing the results of 
this investigation. First, in using venous occlusion plethysmography it is assumed that venous 
pressure is equal to venous collecting cuff pressure. We feel that the eight-minute collection cuff 
period was a sufficient enough duration for us to meet the assumption that collecting cuff 
pressure is equal to venous pressure; However, this was not directly assessed. Second, with our 
study only having evaluated older males and females of a particular physical engagement level 
who have undergone chemotherapy, our results cannot be generalized to all populations. There is 
a potential for cancer patients of differing physical engagement levels to repond differently. 
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CHAPTER 5 
CONCLUSION 
 Results from this study indicate venous compliance is not different among cancer 
survivors who have received neuro-toxic or cardio-toxic chemotherapeutics and healthy 
individuals. Any compliance variations that may exist in persons treated with particular 
chemotherapeutics are not found in an older population that is physically active for 6 months or 
greater. Regardless of having a significantly higher resting heart-rate, cancer survivors had 
similar venous characteristics in their lower extremities as healthy individuals.  
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